ABSTRACT
After anticoagulation has been started in patients with venous thromboembolism (VTE), three issues need to be addressed: the length of therapy, measures to help prevent postthrombotic syndrome, and a basic workup for malignancy in patients with idiopathic VTE.
Footnotes
↵a Dr. Kaatz has disclosed consulting, teaching and speaking, independent contracting (including contracted research), and membership on advisory committees or review panels for the Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Ortho-McNeil, and Johnson and Johnson corporations.
↵b Dr. Lavender has disclosed receiving research support for clinical trials from the Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Daiichi Sankyo corporations.
- Copyright © 2011 The Cleveland Clinic Foundation. All Rights Reserved.